Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry

Akeso Seeks $74 Million in Private Placement; Shares Slide 8%

MT Newswires ·  {{timeTz}}

01:49 AM EDT, 07/08/2022 (MT Newswires) -- Akeso (HKG:9926) is targeting to raise HK$582.5 million ($74.2 million) in a private placement to fund the commercialization and clinical trial of its key cancer drug, according to a Friday disclosure.

The pharmaceutical company is selling 24 million new shares at HK$24.27 apiece through placing agent Morgan Stanley.

The placing shares represent 2.85% of the company's issued share capital as enlarged by the deal.

About 60% of the proceeds will be used for the marketing and clinical studies of Cadonilimab, an immuno-oncology drug developed by Akeso for various indications such as gastric cancer, nasopharyngeal carcinoma and other malignant tumors.

The rest will go towards expediting clinical trials of other products in the pipeline, such as Ivonescimab and Ebronucimab.

The stock fell over 8% in the afternoon trade.

This presentation is for informational and educational use only and is not a recommendation or endorsement of any particular investment or investment strategy. Investment information provided in this content is general in nature, strictly for illustrative purposes, and may not be appropriate for all investors. It is provided without respect to individual investors’ financial sophistication, financial situation, investment objectives, investing time horizon, or risk tolerance. You should consider the appropriateness of this information having regard to your relevant personal circumstances before making any investment decisions. Past investment performance does not indicate or guarantee future success. Returns will vary, and all investments carry risks, including loss of principal. Moomoo makes no representation or warranty as to its adequacy, completeness, accuracy or timeliness for any particular purpose of the above content.

Moomoo is a financial information and trading app offered by Moomoo Technologies Inc.
In the U.S., investment products and services available through the moomoo app are offered by Moomoo Financial Inc., a broker-dealer registered with the U.S. Securities and Exchange Commission (SEC) and a member of Financial Industry Regulatory Authority (FINRA)/Securities Investor Protection Corporation (SIPC).
In Singapore, investment products and services available through the moomoo app are offered through Moomoo Financial Singapore Pte. Ltd. regulated by the Monetary Authority of Singapore (MAS). Moomoo Financial Singapore Pte. Ltd. is a Capital Markets Services Licence (License No. CMS101000) holder with the Exempt Financial Adviser Status. This advertisement has not been reviewed by the Monetary Authority of Singapore.
In Australia, financial products and services available through the moomoo app are provided by Futu Securities (Australia) Ltd, an Australian Financial Services Licensee (AFSL No. 224663) regulated by the Australian Securities and Investment Commission (ASIC). Please read and understand our Financial Services Guide, Terms and Conditions, Privacy Policy and other disclosure documents which are available on our websites https://www.futuau.com and https://www.moomoo.com/au. Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd. and Futu Securities (Australia) Ltd are affiliated companies.